Skip to content

Depression: all studies

Page 543 of 1,034: studies 5,421 to 5,430 of 10,336, newest first. Back to the depression overview

Research

Pharmacokinetics and brain distribution of ketamine after nasal administration.

Journal of Pharmaceutical and Biomedical Analysis October 15, 2025 Zihe Yang, Linjie Li, Bin Deng et al. 3 citations

Major depressive disorder is a severe mental condition characterized by abnormalities in the structure and function of the brain. Ketamine is a novel antidepressant that has rapid effects on depression. This drug is clinically used to treat depression in patients with acute suicidal ideation or behavior. It is typically administered at a dose of 84 mg. However, the distribution of ketamine in...

DOI: 10.1016/j.jpba.2025.116945 (opens in new tab) Full text (opens in new tab) Brain region distribution Hplc-ms/ms Intranasal administration Pharmacokinetics +5

TREATING CHRONIC SCHIZOPHRENIA AND COMPLEX TRAUMA THROUGH JUNGIAN DREAMWORK: A PRISON-BASED CASE STUDY

LIFE International Journal of Health and Life-Sciences October 14, 2025 Dustin Warden

This case study documents the integrative treatment of a woman with chronic schizophrenia, complex PTSD, and comorbid anxiety and depression, incarcerated during the COVID-19 pandemic. Her primary symptoms included persistent hallucinations, trauma-driven nightmares, and emotional dysregulation. Traumatic themes of incest, supernatural forces, and violent dream figures dominated her inner...

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Psychedelics October 14, 2025 Mingming Zhao, Jianjun Yang, Kenji Hashimoto

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...

Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment

Psychedelics October 14, 2025 Sha Jin, H.y. Wang, Xiaohui Wang

Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable health burden worldwide with high prevalence, disabling symptoms, and scant efficacy of available treatments. Chronic stress is a major contributor to the origin and development of these conditions, to the detriment of both individual and, by...

DOI: 10.61373/pp025v.0038 (opens in new tab) Anxiety Context archaeology Mental health Perspective graphical +8

Structure-Guided Design of Novel 5-HT 2A Partial Agonists as Psychedelic Analogues with Antidepressant Effects

Journal of Medicinal Chemistry October 14, 2025 Rongyan Li, Hong Yan, Yujin Chen et al. 1 citation

Depression is primarily treated with selective serotonin reuptake inhibitors (SSRIs), which are limited by delayed onset of effects and low rates of remission. Recent studies showed that serotonergic psychedelics such as psilocybin can reduce depressive symptoms both rapidly and enduringly. Such effects have been associated with the activation of the serotonin 2A (5-HT2A) receptor in the...

Effects of Buddhist Walking Meditation, Walking Meditation or Mindful Walking on the Health of Adults and Older Adults: A Systematic Review

Psychiatry International October 13, 2025 Felipe Montalva-Valenzuela, Eduardo Guzmán-Muñoz, Gérson Ferrari et al. 1 citation

Background: Physical activity is essential for good health and human well-being, yet one-third of adults worldwide fail to achieve the recommended weekly physical activity. Buddhist Walking Meditation (BWM), Walking Meditation (WM), or Mindful Walking (MW) is a mindfulness practice characterized by mind–body interaction, seeking to promote people’s well-being. Therefore, this systematic review...

DOI: 10.3390/psychiatryint6040122 (opens in new tab) Meditation Mindfulness Psychological intervention Intervention counseling +8

Psychedelics for the Treatment of Substance Use Disorder

Pharmaceutical Science October 13, 2025 Berta Fumàs, David Pubill, Raúl López‐arnau et al.

Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as...

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics

ACS Chemical Neuroscience October 13, 2025 Rajiv Agrawal, Daniel J. Gillie, Alison E. Mungenast et al. 8 citations

Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical neurons has been hypothesized to explain the rapid and enduring therapeutic effects of psychedelics and the dissociative anesthetic ketamine. However, safety concerns related to hallucinogenic/dissociative properties have limited the addressable...

Alucinógenos como terapia complementar no manejo da depressão: uma revisão integrativa

Brazilian Journal of Implantology and Health Sciences October 10, 2025 Pedro M. P. Raposo, Lucas Almeida Gonçalves, Ana Laura de Araújo Caetano et al.

A depressão é um transtorno de grande impacto clínico e social, frequentemente resistente ao tratamento convencional, o que motiva a busca por estratégias terapêuticas complementares. Psicodélicos como a psilocibina e o MDMA têm se destacado por induzir respostas rápidas e duradouras em sintomas depressivos. Esta revisão integrativa analisou 14 estudos publicados entre 2015 e 2024, selecionados...

DOI: 10.36557/2674-8169.2025v7n10p559-584 (opens in new tab) MDMA Informed consent Palliative care Depression economics +3

Psychedelics in Practice: Science, Safety, and the Future of Healing

PROCEEDINGS OF THE SLIIT INTERNATIONAL CONFERENCE ON ADVANCEMENTS IN SCIENCES AND HUMANITIES [SICASH] October 10, 2025 Renee Ireland

Psychedelic-assisted therapies are re-emerging as credible options in psychological care amid a high global burden of mental ill-health and limited response to first-line treatments. Once marginal, psychedelics are now part of mainstream research and policy debate, while remaining illegal or tightly restricted in many jurisdictions. Classic and atypical compounds (e.g., psilocybin, MDMA) act...